Drug-class evidence
Orforglipron (investigational) clinical trials
1 pivotal trial of orforglipron (investigational), spanning Orforglipron (now approved as Foundayo). 272 total participants across the published evidence base.
What we know about orforglipron (investigational)
Orforglipron (LY3502970) is an investigational once-daily ORAL small-molecule (non-peptide) GLP-1 receptor agonist — it is NOT FDA-approved. Its Phase 2 obesity trial reported up to ~14.7% mean weight loss at 36 weeks, notable for being an oral pill rather than an injection; Phase 3 trials are ongoing.
Percent weight loss across Orforglipron (investigational) obesity trials
Primary-endpoint percent body-weight change for the published orforglipron (investigational) weight-management trials. Conducted on FDA-approved branded products only.
| Trial | NCT ID | Percent weight loss |
|---|---|---|
| Orforglipron Phase 2 (obesity) · Orforglipron (now approved as Foundayo) | NCT05051579 | 14.7% |
Effect sizes across orforglipron (investigational) trials
| Trial | Brand | Indication | Weight loss | A1C reduction | N · year |
|---|---|---|---|---|---|
| Orforglipron Phase 2 (obesity) | Orforglipron (now approved as Foundayo) | Obesity / overweight | 14.7% | — | 272 · 2023 |
All orforglipron (investigational) trials
Trials cited are for the FDA-approved branded products containing orforglipron (investigational). Compounded versions have not been studied in equivalent randomized controlled trials. GLP1Zoom does not provide medical advice; discuss treatment with your prescribing clinician. Full disclaimer.